OR WAIT null SECS
© 2022 MJH Life Sciences and Formulary Watch. All rights reserved.
© 2022 MJH Life Sciences™ and Formulary Watch. All rights reserved.
November 26, 2021
Across all payers, the use of generic statins has resulted in a savings of $11.9 billion annually.
November 12, 2021
Besremi is the first interferon approved to treat a disease that causes the overproduction of red blood cells.
If approved, Jardiance would be the first treatment for adults across the full spectrum of heart failure regardless of ejection fraction.
October 21, 2021
Treating and managing patients with paroxysmal nocturnal hemoglobinuria is expensive and requires constant surveillance by the provider and health plan.
October 07, 2021
Investigators found only small differences in the change in LDL-C levels in the incentive groups versus the control group
Gavreto treats patients with advanced lung care and Arcalyst treats patients with recurrent pericarditis.
September 27, 2021
Repatha is now available for children 10 and older to lower low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolemia.
September 13, 2021
Jardiance demonstrated a 21% relative risk reduction for the composite primary endpoint of cardiovascular death or hospitalization for heart failure.
August 31, 2021
The full results from the Emperor-Preserved trial show Jardiance reduces the risk of hospital and death from heart failure.
August 24, 2021
Preliminary research shows Anplag could be repurposed as a heart failure treatment at a lower cost.